Our data provide proof‐of‐principle that an active immunization strategy can reduce NOTCH3 aggregation in a pre‐clinical model of CADASIL and thus may be beneficial also in the treatment of CADASIL. The gene discussed is NOTCH3; the disease is CADASIL.